Keywords
Adiponectin
Statins
Lovastatin
Atorvastatin
How to Cite
Abstract
Studies linking the statins effect over adipocytokines levels have reported controversies; therefore, it is necessary to contribute to elucidate the relationship between them. The objective of this study was to compare leptin and adiponectin serum concentrations, according to the statin regimen. Tha present is an observational, cross-sectional, and relational-level study. Data of clinical history for 76 participants were obtained, and leptin and adiponectin were quantified by using ELISA sandwich technique. The relational analysis was performed using U-Mann-Whitney and H-Kruskal-Wallis. Serum leptin concentrations were homogeneous and independent of the statin regimen; on the contrary, those of adiponectin were lower in those who consumed 40 mg / day of atorvastatin. Atorvastatin at 40 mg / day is associated with plasma adiponectin concentrations lower than adiponectinemia in participants who were treated with other statin regimens. It is important for the scientific community to research on these biomarkers in order to elucidate relationships that will allow a more accurate prediction of the impact, especially atorvastatin at intermediate and high doses, as a drug with greater benefits against cardiovascular events and metabolic syndrom.References
Rodríguez-Rodríguez E, Perea JM, López-Sobaler AM, Ortega RM. Obesidad, resistencia a la insulina y aumento de los niveles de adipoquinas: importancia de la dieta y el ejercicio físico. Nutr Hosp. 2009;24(4):415-21. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112009000400004.
Quenan YE, Osorio JH. Relación entre obesidad, adipocitoquinas y osteoatrosis: Una revisión. Univ Salud. 2017;19(3):410-8. Doi: https://doi.org/10.22267/rus.171903.103.
Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: A potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018;39:151-8. Doi: https://doi.org/10.1016/j.cytogfr.2018.01.004
Noguchi T, Kobayashi J, Yagi K, Nohara A, Yamaaki N, Sugihara M, et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study. Atherosclerosis. 2011;217(1):165-70. Doi: http://dx.doi.org/10.1016/j.atherosclerosis.2011.02.012.
Sahebkar A. Head-to-head comparison of fibrates versus statins for elevation of circulating adiponectin concentrations: a systematic review and meta-analysis. Metabolism. 2013;62(12):1876-85. Doi: https://doi.org/10.1016/j.metabol.2013.08.017
Szotowska M, Czerwienska B, Adamczak M, Chudek J, Wiecek A. Effect of Low-Dose Atorvastatin on Plasma Concentrations of Adipokines in Patients with Metabolic Syndrome. Kidney Blood Press Res. 2012;35(4):226-32. Doi: https://doi.org/10.1159/000332403.
Mayorga MP. El adipocito como órgano endocrino. Implicaciones fisiopatológicas y terapéuticas. Rev Med. 2007;15(2):225-42. Disponible en: http://www.scielo.org.co/pdf/med/v15n2/V15n2a10.pdf.
Marcano Y, Torcat J, Ayala L, Verdi B, Lairet C, Maldonado M, et al. Funciones Endocrinas del Tejido Adiposo. Revisión. Rev Venez Endocrinol Metab. 2006;4(1):15-21. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S1690-31102006000100003.
Torres DG, González MFC, Morales RC, Rodríguez MB, Arteaga IR. Tejido adiposo como glándula endocrina. Implicaciones fisiopatológicas. Rev Finlay. 2011;1(2):131-51. Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/39/1209.
Alhadeff AL, Conway SM, Ong ZY, Wald HS, Roitman MF, Grill HJ. Central leptin signaling transmits positive valence. Brain Res. 2019;1724:1-23. Doi: http://dx.doi.org/10.1016/j.brainres.2019.146441.
Solberg R, Aas V, Thoresen GH, Kase ET, Drevon CA, Rustan AC, et al. Leptin expression in human primary skeletal muscle cells is reduced during differentiation. J Cell Biochem. 2005;96(1):89-96. Doi: http://dx.doi.org/10.1002/jcb.20521.
Zhang Y, Chua S. Leptin Function and Regulation. Compr Physiol. 2017;8(1):351-69. Doi: http://dx.doi.org/10.1002/cphy.c160041.
Gómez-Romero P, Alarcón-Sotelo A, Rodríguez-Weber F, Díaz-Greene E. La adiponectina como blanco terapéutico. Med Interna México. 2017;33(6):770-7. Doi: https://doi.org/10.24245/mim.v33i6.1672.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-92. Doi: http://dx.doi.org/10.1172/JCI29126.
Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci. 2017;18(6):1-17. Doi: http://dx.doi.org/10.3390/ijms18061321.
Lestavel S, Fruchart JC. Lipoprotein receptors. Cell Mol Biol Noisy--Gd Fr. 1994;40(4):461-81. Disponible en: https://pubmed.ncbi.nlm.nih.gov/8061563/.
Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fiévet C, Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 1999;452(3):160-4. Doi: http://dx.doi.org/10.1016/s0014-5793(99)00632-8.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. Doi: https://doi.org/10.1093/eurheartj/ehz455.
Velarde GP, Choudhary N, Bravo-Jaimes K, Smotherman C, Sherazi S, Kraemer DF. Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2021;31(2):634-40. Doi: http://dx.doi.org/10.1016/j.numecd.2020.10.002.
Qu H-Y, Xiao Y-W, Jiang G-H, Wang Z-Y, Zhang Y, Zhang M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res. 2009;26(4):958-64. Doi: http://dx.doi.org/10.1007/s11095-008-9798-6.
Sahebkar A, Giua R, Pedone C. Impact of Statin Therapy on Plasma Leptin Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials: Impact of statin therapy on leptin plasma concentration: a meta-analysis. Br J Clin Pharmacol. 2016;82(6):1674-84. Doi: http://dx.doi.org/10.1111/bcp.13086.
Adiponectin-ELISA KAPME09 [Internet]. DIASource; 2020. Disponible en: https://www.diasource-diagnostics.com/IVD-Products/ImmunoAssays/Diabetes-Metabolism/Adiponectin/Adiponectin-ELISA-96-tests
Leptin-ELISA KAP2281 [Internet]. DIASource; 2020. Disponible en: https://www.diasource-diagnostics.com/IVD-Products/ImmunoAssays/Diabetes-Metabolism/Leptin/Leptin-ELISA-96-tests
IBM SPSS Software [Internet]. 2021 [citado 6 de abril de 2021]. Disponible en: https://www.ibm.com/co-es/analytics/spss-statistics-software
Ministerio de Salud de Colombia. Resolución 8430 de 1993 - Colombia [Internet]. www.redjurista.com. [citado 6 de abril de 2021]. Disponible en: https://www.redjurista.com/Documents/resolucion_8430_de_1993.aspx
Bulcão C, Giuffrida FMA, Ribeiro-Filho FF, Ferreira SRG. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Braz J Med Biol Res. 2007;40(2):229-35. Doi: https://doi.org/10.1590/S0100-879X2006005000042.
Morales Clavijo M, Carvajal Garcés CF. Obesidad y resistencia a la leptina. Gac Médica Boliv. 2010;33(1):63-8. Disponible en: http://www.scielo.org.bo/pdf/gmb/v33n1/a13.pdf.
Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab. 1996;81(12):4406-13. Doi: http://dx.doi.org/10.1210/jcem.81.12.8954050.
Ostlund RE, Yang JW, Klein S, Gingerich R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab. 1996;81(11):3909-13. Doi: https://doi.org/10.1210/jcem.81.11.8923837.
Koh KK, Quon MJ, Han SH, Lee Y, Park JB, Kim SJ, et al. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 2011;146(3):319-25. Doi: http://dx.doi.org/10.1016/j.ijcard.2009.07.002.
Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol. 2008;586(1-3):259-65. Doi: http://dx.doi.org/10.1016/j.ejphar.2008.02.042.
Buldak L, Dulawa-Buldak A, Labuzek K, Okopien B. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. Int J Clin Pharmacol Ther. 2012;50(11):805-13. Doi: http://dx.doi.org/10.5414/CP201735.
Al-Azzam SI, Alkhateeb AM, Alzoubi KH, Alzayadeen RN, Ababneh MA, Khabour OF. Atorvastatin treatment modulates the interaction between leptin and adiponectin, and the clinical parameters in patients with type II diabetes. Exp Ther Med. 2013;6(6):1565-9. Doi: http://dx.doi.org/10.3892/etm.2013.1347.
Krysiak R, Żmuda W, Marek B, Okopień B. Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels. Endokrynol Pol. 2016;67(3):271-6. Doi: http://dx.doi.org/10.5603/EP.a2016.0019.
Viso M, Porrello B, Rauseo D, Reverón D, Rivas B, Galdona E, et al. Adiponectina y su relación con obesidad, insulinorresistencia y síndrome metabólico en adultos de la cohorte cdc de canarias en Venezuela. Rev Venez Endocrinol Metab. 2013;11(2):76-86. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S1690-31102013000200004.
Greenhill C. Obesity-induced hypermethylation of adiponectin gene. Nat Rev Endocrinol. 2015;11(9):504-504. Doi: http://dx.doi.org/10.1038/ncomms8585.
Khan UI, Wang D, Sowers MR, Mancuso P, Everson-Rose SA, Scherer PE, et al. Race-ethnic differences in adipokine levels: the Study of Women’s Health Across the Nation (SWAN). Metabolism. 2012;61(9):1261-9. Doi: http://dx.doi.org/10.1016/j.metabol.2012.02.005.
Stepien M, Stepien A, Banach M, Wlazel RN, Paradowski M, Rizzo M, et al. New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis. Angiology. 2014;65(4):333-42. Doi: http://dx.doi.org/10.1177/0003319713485807.
Qian Y, Gurley BJ, Markowitz JS. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. J Clin Psychopharmacol. 2019;39(5):462-71. Doi: http://dx.doi.org/10.1097/JCP.0000000000001089.
Krasulova K, Holas O, Anzenbacher P. Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity. Mol J Synth Chem Nat Prod Chem. 2017;22(11):1-14. Doi: http://dx.doi.org/10.3390/molecules22111879.
Ramos PM. Del concepto de estatinas de alta potencia a los efectos extralipídicos de las estatinas. Rev Esp Cardiol. 2015;15(1):22-7. Doi: http://dx.doi.org/10.1016/S1131-3587(15)70121-4.
García-Sabina A, Gulín-Dávila J, Sempere-Serrano P, González-Juanatey C, Martínez-Pacheco R. Consideraciones específicas en la prescripción e intercambio terapéutico de estatinas. Farm Hosp. 2012;36(2):97-108. Doi: http://dx.doi.org/10.1016/j.farma.2011.02.010.
Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16(9):809-22. Doi: http://dx.doi.org/10.1080/17425255.2020.1801634
Gallo P, De Vincentis A, Pedone C, Nobili A, Tettamanti M, Gentilucci UV, et al. Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med. 2019;65:51-7. Doi: http://dx.doi.org/10.1016/j.ejim.2019.05.002.
Guan Z-W, Wu K-R, Li R, Yin Y, Li X-L, Zhang S-F, et al. Pharmacogenetics of statins treatment: Efficacy and safety. J Clin Pharm Ther. 2019;44(6):858-67. Doi: http://dx.doi.org/10.1111/jcpt.13025
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2022 Universidad del Magdalena